CLAIMS

1. A solid pharmaceutical composition in the form of an immediate release tablet, comprising:
   i. pregabalin particles having a particle size distribution with a D(50) from 100 pm to 420 pm, and/or pregabalin particles having a particle size distribution with a D(90) from 300 pm to 850 pm, both measured by volume,
   ii. at least one filler, and
   iii. at least one lubricant,

wherein the immediate release tablet is prepared by direct compression, and wherein the filler (ii) is a cellulose derivative.

2. The solid pharmaceutical composition according to claim 1, wherein the pregabalin particles (i) are characterized by having a particle size distribution with a D(50) from 120 μm to 400 μm.

3. The solid pharmaceutical composition according to any of the preceding claims, wherein the pregabalin particles (i) are characterised by having a particle size distribution with D(90) from 320 μm to 800 μm.

4. The solid pharmaceutical composition according to any of the preceding claims, wherein the cellulose derivative is characterized by having particles size distribution of D(50) below 200 μm.

5. The solid pharmaceutical composition according to claim 4, wherein the cellulose derivative is selected from methyl cellulose, microcrystalline cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, and mixtures thereof, preferably the cellulose derivate is microcrystalline cellulose.

6. The solid pharmaceutical composition according to any the preceding claims, wherein the lubricant (iii) is an alkaline stearate.

7. The solid pharmaceutical composition according to claim 6, wherein the alkaline stearate is selected from magnesium stearate, calcium stearate and mixtures thereof, preferably the alkaline stearate is magnesium stearate.

8. The solid pharmaceutical composition according to anyone of the preceding claims, wherein the filler (ii) is present in an amount from 45% to 80% by weight, based on the total weight of the composition, preferably in an amount from 45% to 70%, based on the total weight of the composition.

9. The solid pharmaceutical composition according to any of the preceding claims, wherein the pregabalin particles (i) are present in amount from 15% to 50% by weight, based on the total weight of the composition, preferably from 25% to 45% by weight, based on the total weight of the composition.

10. The solid pharmaceutical composition according to any of the preceding claims, comprising:

i. from 15% to 50% by weight of pregabalin particles having a particle size distribution with a D(50) from 100 μm to 420 μm, and/or pregabalin particles having a particle size distribution with a D(90) from 300 μm to 850 μm, both measured by volume,
ii. from 45% to 80% by weight of at least one filler and
iii. from 0.1% to 5% by weight of at least one lubricant,

wherein the percentage by weight is relative to the total weight of the composition and wherein the immediate release tablet is prepared by direct compression, and wherein the filler (ii) is a cellulose derivative.

11. The solid pharmaceutical composition according to any of the preceding claims, comprising:

i. from 25% to 45% by weight of pregabalin particles having a particle size distribution with a D(50) from 100 μm to 420 μm, and/or pregabalin particles having a particle size distribution with a D(90) from 300 μm to 850 μm, both measured by volume,
ii. from 45% to 70% by weight of at least one filler and
iii. from 0.1% to 5% by weight of at least one lubricant,

wherein the percentage by weight is relative to the total weight of the composition and wherein the immediate release tablet is prepared by direct compression, and wherein the filler (ii) is a cellulose derivative.

12. The solid pharmaceutical composition according to any of the preceding claims, wherein the tablets are coated with a functional polymer, which acts as a filmogenic agent.

13. The solid pharmaceutical composition according to any of the preceding claims, wherein the content of degradation products is less than 0.20% by weight, preferably less than 0.10% by weight based on the total weight of the composition.

14. A process for preparing the solid pharmaceutical composition according to any of the preceding claims, comprising at least the following steps:

a) Providing pregabalin particles having a particle size distribution with a D(50) from 100 to 420 μm and/or a D(90) from 300 μm to 850 μm, both measured by volume, and at least one filler, wherein the filler is a cellulose derivative;
b) Mixing the ingredients of step a) in a suitable mixer to achieve a homogeneous mixture; and
c) Mixing the blend of step b) with at least one lubricant, until a homogeneous powder is obtained;
d) Compressing the powder mixture of step c) into tablets
e) Optionally, coating the tablets of step d), with a functional polymer which acts as a filmogenic agent.

15. A process for preparing according to claim 14, wherein the pregabalin particles of step a) have a D(50) from 120 to 400 μm and/or a D(90) from 320 μm to 800 μm.